Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q1 2025 ▲▼ | Q2 2025 ▲▼ | Change ▲▼ | Q1 2025 ▲▼ | Q2 2025 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Newamsterdam Pharma Company ORDINARY SHARES | 10,935,310 | 10,632,113 | -303,197 | $223.85M | $192.55M | 52.16% | -$31.30M |
| Dyne Therapeutics, Inc.(DYN) | 5,462,846 | 5,462,846 | 0 | $57.14M | $52.01M | 14.09% | -$5.14M |
| Replimune Group, Inc.(REPL) | 3,909,696 | 3,909,696 | 0 | $38.12M | $36.32M | 9.84% | -$1.80M |
| Engene Holdings Inc COM | 9,632,561 | 9,632,561 | 0 | $43.15M | $35.06M | 9.50% | -$8.09M |
| Bicycle Therapeutics PlcADS | 3,452,330 | 3,452,330 | 0 | $29.31M | $23.99M | 6.50% | -$5.32M |
| Astria Therapeutics Inc | 3,822,537 | 4,107,537 | +285,000 | $20.41M | $23.41M | 6.34% | +$3.00M |
| Rapt Therapeutics Inc | 0 | 440,176 | +440,176 | $0 | $3.45M | 0.93% | +$3.45M |
| Engene Holdings IncW EXP 10 31 2028 *W EXP 10/31/202 | 2,878,148 | 2,878,148 | 0 | $1.73M | $2.36M | 0.64% | +$632.0K |